|
|
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa |
 Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days. |
|
|
|
|
Friday, 11 September 2009 |
 |
 |
 |
|
|
New Data From CLARITY Study on Disease Activity in MS Patients |
 Merck KGaA has announced new data from a post-hoc analysis of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using a short-course of Cladribine Tablets (the proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The data from this post-hoc analysis of the CLARITY study were presented at the 25th congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Duesseldorf, Germany.(2)
|
|
|
|
Tuesday, 22 September 2009 |
|
|
|
|
|
Nycomed sustains commitment to Russia-CIS and invests in new pharmaceutical production plant |
 Nycomed today announced its decision to invest in a state-of-the-art pharmaceutical production plant near the city of Yaroslavl in Russia. The company plans to invest between €65 million to €75 million. The new facility will produce medicines for the local Russia-CIS market, which contributes 10% to Nycomed's turnover and plays an important role in the company's growth strategy. |
|
|
|
|
Tuesday, 15 September 2009 |
|
|
|
|
|
Global Study Provides Additional Information About an Intensified Dose-Regimen of Plavix® |
 The OASIS study group has presented initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona. Sanofi-aventis (EURONEXT: SAN, and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY), co-commercialization and co-development partners for PLAVIX® (clopidogrel bisulfate), were sponsors of the study.
|
|
|
|
Wednesday, 21 October 2009 |
|
|
|
|
|
Diabetes Conversation Map(TM) Education Tools Celebrate One-Year Anniversary |
 This October marks the one-year anniversary of the international launchof the ground-breaking diabetes Conversation Map(TM) education tools. Created by Healthy Interactions, a global leader in health education, in collaboration with the International Diabetes Federation (IDF), Eli Lilly and Company and other leading diabetes experts, the unique Conversation Map(TM) education tools have been implemented in 68 countries, excluding the United States, in 31 different languages in the last 365 days. |
|
|
|
|
|
|
|
|
Page 1 of 89 |
